iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting

iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting

Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of two posters on its novel A2Areceptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rdAnnual Meeting, taking place from November 7-11, 2018 in Washington, D.C.

“The expanding breadth of knowledge and understanding of the suppressive tumor microenvironment has been  fundamental to the design and development of iTeos’ best-in-class oncology drug candidates,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “The preclinical data presented at SITC demonstrate how our adenosine A2Areceptor antagonist can maintain potency in a high adenosine environment, uniquely evading the limitations faced by repurposed A2Areceptor antagonists. Enabled by the same approach, our TIGIT antagonist monoclonal antibody induces strong anti-tumor efficacy in both monotherapy and in combination with anti-PD1 for more potent activity. We are excited by these findings and look forward to advancing both of these programs into the clinic in the first half of 2019.” 

The details of the two presentations are as follows:

Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and shows best-in class characteristics.

Date & Time:Friday, November 9, 2018; 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Authors: Houthuys, et al.

Poster Number: 667

Key Takeaways:

  • Adenosine levels are elevated in many tumor microenvironments, promoting tumor immune evasion
  • EOS100850 reverses inhibition of immune cell function by potently inhibiting A2A receptor signalling 
  • In both in vitroand in vivotumor models, EOS100850 induces long standing and specific immune protection


Title: Antitumor efficacy of anti-TIGIT antagonist antibody EOS884448 is mediated by a dual mechanism of action involving restoration of T cell effector functions and preferential depletion of Tregs.

Date & Time: Saturday, November 10, 2018; 12:45 – 2:15 p.m. and 6:30 – 8:00 p.m.

Authors: Hoofd, et al.

Poster Number: 666

Key Takeaways:

  • EOS884448 is a fully human, potent and specific disruptor of the immunosuppressive binding of CD155 to TIGIT in the tumor microenvironment
  • Due to its Fc receptor engagement, EOS884448 not only inhibits CD155 binding but also targets for destruction cells that over-express TIGIT (e.g. Tregs) in the tumor microenvironment
  • EOS884448 exhibits efficacy in in vivotumor models and is more effective when combined with other checkpoint inhibitors

About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850)

The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models.

About iTeos’ Human Anti-TIGIT Antibody (EOS884448)

TIGIT is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models.

About iTeos Therapeutics 

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics


Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700


Sarah McCabe and Carl Mauch

Stern Investor Relations, Inc.

+ 1 212 362 1200

Related news



    iTeos Therapeutics SA, a drug discovery company focused on the development of immunomodulators for cancer therapy, today announced the successful closing of its Series A equity financing round. iTeos, a joint spin-off of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain (UCL), raised €3.0 million from LICR, Hunza Ventures SCA, Life Sciences Research Partners, VIVES Louvain Technology Fund and several business angels. This financing complements a €6 million non-dilutive grant from the Belgian Walloon Government, which was received in December 2011. Cancer immunotherapy has gained momentum in the two last years because of the clinical success of new immunotherapeutic treatments. Immunotherapy can harness the immune system to selectively destroy tumors and limit the risk of recurrences, with very limited side effects. However, the success of cancer immunotherapy has been limited by the ability of tumors to block the immune response, something known as immunosuppression. Scientists are now working to better understand the mechanisms responsible for immunosuppression, in order to devise strategies to overcome them. This is what iTeos’ research program strives to do: develop small-molecule immunomodulators that can increase the efficacy of cancer immunotherapy, as well as leverage the spontaneous anti-tumor immune response. “We believe that the efficacy of most cancer therapies — not only immunotherapy — will be greatly enhanced by the control of tumor immunosuppressive mechanisms,” said Benoît Van den Eynde, Brussels Branch Director at LICR, UCL Professor and co-founder of iTeos. “Our first strategy will aim to combine existing vaccines with new immunomodulators based on technology that was licensed from LICR. Thereafter we will explore combinations with other cancer therapies,” added Van den Eynde. “iTeos brings together the world-class expertise of LICR in immunotherapy and tumor immunology with a team of drug discovery experts to develop innovative treatments against severe diseases such as lung, pancreatic and liver cancers,” said iTeos co-founder and CEO Michel Detheux. “With substantial funding now in place, iTeos is well-positioned to execute its ambitious strategy over the next several years by accelerating the clinical development of its flagship program, as well as two additional preclinical programs,” added Detheux. “Moving early-stage research advances from LICR scientists into later-stage clinical testing for the benefit of patients is a priority for the Institute,” said Jonathan Skipper, Executive Director of Technology Development at LICR. “iTeos will have access to LICR’s expertise and infrastructure so that candidate therapeutics can be rapidly tested,” added Skipper. “We are very proud to establish a joint spin-off company between two prestigious institutes — LICR and the de Duve Institute at UCL. iTeos combines a solid pipeline with the expertise to develop a new discovery platform in immunomodulation," concluded Philippe Durieux, CEO of SOPARTEC and managing director of VIVES Louvain Technology Fund. The iTeos Board is comprised of industrial, scientific and financial experts, including Philippe Guinot as independent Chairman, Natacha Beaumont (Managing Director, Hunza Ventures), Chris Buyse (CFO, ThromboGenics), Philippe Durieux (VIVES) and Jonathan Skipper (Executive Director of Technology Development, LICR). The Scientific Committee comprises Jean-Yves Bonnefoy (VP R&D, Transgene), Pierre Coulie (UCL) and Douglas Fearon (Cambridge University). Eubelius was the legal advisor of the company in this transaction. All parties involved decided not to disclose any further financial information regarding this transaction. For more information, please visit or contact Michel Detheux at +32478034600, or by email at About iTeos Therapeutics SA Based in Gosselies, Belgium, iTeos Therapeutics SA is a private biotechnology company with a focus on developing small-molecule immunomodulators for cancer treatment. Originating from a partnership between the Ludwig Institute for Cancer Research and de Duve Institute at the Université catholique de Louvain, iTeos Therapeutics SA is led by management and research teams with proven track records in tumor immunology, immunotherapy, drug discovery and development. About Ludwig Institute for Cancer Research (LICR) LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research. For more information, please visit About Life Sciences Research Partners Life Sciences Research Partners (formerly called D Collen Research Foundation) was founded by Emeritus Professor Désiré Collen in 1988. The purpose of Life Sciences Research Partners is, without any profit-making intentions, to carry out, promote and support scientific research in general and biomedical and biotechnological research in particular. The specific activities by which the purposes of the association will be realized are among others the awarding of research grants, research mandates and traveling scholarships, the organization of scientific congresses and symposia, financial support of publications, and any other related activities that support or help to propagate the advancement of science. In addition, the association may conduct any other activity, that contributes directly or indirectly to its non-profit purpose, including commercial and profitable activities within legal boundaries, on condition that the profit thereof be exclusively spent on the non-profit purposes of the association. For more information, please visit About VIVES-Louvain Technology Fund VIVES-Louvain Technology Fund is a multi-sectorial technology investment fund that invests in spin-offs ofUniversité catholique de Louvain (UCL) as well as start-ups in Belgium and neighboring countries. The objective of the fund is to invest in the development of start-ups, from technological validation through to commercial maturity. The funds (VIVES 1 of EUR 15 mio and VIVES 2 of EUR 43mio) are managed by SOPARTEC, the technology transfer company of the Université catholique de Louvain (UCL). Through Louvain Technology Transfer Office (LTTO), SOPARTEC and the University´s Research Administration (ADRE) are in charge of the overall technology transfer process. This covers the financing of research contracts, the identification of inventions within the laboratories, the protection and management of intellectual property,the technological maturation and the commercialization (through licensing and/or spin-off). More specifically, SOPARTEC coordinates the management of licensing agreements and the technological maturation of UCL spin-offs. More than 50 spin-offs, which today generate more than 3,000 jobs, have been created in whole or part from the results of research conducted at the UCL. These include Ion Beam Application (IBA), I.R.I.S. Group, IbT, Telemis, Alterface, Cissoid, Viridaxis, Promethera, Greenwatt, etc. For more information, please visit About Hunza Ventures SCA Hunza Ventures is a venture capital firm dedicated to the life sciences and information technology currently managing in excess of €20 million. Founded in 1998, Hunza Ventures has built a balanced portfolio of companies developing novel approaches and best-in-class products. With its strong sector expertise and through its multidisciplinary team and entrepreneurial approach, the fund prides itself in truly partnering with its portfolio companies. For more information, please visit About UCL Founded in 1425, one of Europe’s oldest universities, UCL has 27,289 students on six sites (Louvain-la-Neuve, Bruxelles (Woluwe and Saint-Gilles), Mons, Tournai, Charleroi). UCL educates almost one in every two French-speaking Belgians, and attracts every year 4,000 international students from around the globe (a number of programmes are given in English). UCL trains students in all disciplines, from beginner’s level through doctorate level and on to adult continuing education. Teaching is based on solid research and innovation. UCL is also one of the 22 European Universities to have received the ECTS label, a European Union recognition of the quality of its management of international exchanges. In the latest QS World University Rankings (2011), UCL was located at the 125e position, which makes it the first French speaking university of Belgium. For more information, please visit About de Duve Institute Founded in 1974 by Nobel Prize Laureate Christian de Duve, the de Duve Institute is a renowned multidisciplinary biomedical research institute located on the Brussels campus of the Université catholique de Louvain (UCL), next to the Cliniques Universitaires Saint-Luc. It hosts several laboratories of the Faculty of Medicine of UCL, as well as the Brussels Branch of the Ludwig Institute for Cancer Research. Research priorities at the de Duve Institute are based on three principles: (i) priority to fundamental research and to the freedom of the investigators, (ii) special attention to medical benefits potentially resulting from fundamental discoveries (iii) multidisciplinary collaboration within a critical mass of competences. For more information, please visit

  • iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

    iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

    Cambridge, MA  and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 10:50 a.m. ET in New York, NY.

  • iTeos Therapeutics Announces New  Scientific Advisory Board Members
    A2a Inhibitor Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Announces New Scientific Advisory Board Members

    Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics   Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200